SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today provided an update on the timing of its Phase II adjunctive therapy trial with ACP-103 in patients with schizophrenia. ACADIA reported that enrollment in the clinical trial is significantly ahead of schedule, which should enable the company to report top-line results for the complete 400-patient clinical trial during the first quarter of 2007, ahead of earlier expectations. Given the rapid enrollment and opportunity to expedite results for the complete study, ACADIA will no longer perform an interim analysis based on the first 200 patients, which had been planned to be conducted by the end of 2006.
